Category Archives: Psoriasis

Awards season is in full swing, and now that weve all had some time to digest the Will SmithChris Rock slap at the Oscars last Sunday, its time to turn our collective attention to the Grammys. Below, find all the details you need on how to watch the 2022 Grammy Awards, on TV, livesteam, or online:

The 64th Grammy Awards will be held on Sunday, April 3, at 8 p.m. E.T.

For the first time, this years Grammys will be held in Las Vegas, so expect plenty of ads for casinos and strip jokes from presenters.

The Grammys will be televised live on CBS, and if you have cable, thats probably your easiest route toward taking in all the award-winning performances.

Cable subscribers can stream the Grammys live on cbs.com and the CBS app by logging in with their provider, but if youre a cord-cutter, dont worry, all is not lost: You can access the ceremony through Paramount+, the official streamer of the Grammys, or through subscriptions to Hulu Live TV, YouTubeTV, AT&T TV, and FuboTV. (Pro tip: Take advantage of the free trial that many of these platforms offer!)

Grammys 2022 Red Carpet: See All The Celebrity Dresses, Outfits, And Looks Here

Photo: Getty Images

Jared Leto in Gucci

Read original article here

Go here to read the rest:
How to Watch the 2022 Grammy Awardson TV or Online - Verve Times

The first accurate medical discussion of psoriasis dates back to 1801, but the disease itself is much older. In fact, its very name is borrowed from an ancient Greek word meaning an itchy or scaly condition. About 7 million Americans are plagued by this itching and scaling, and many of them have serious complications involving other organs. Although psoriasis is classified as a dermatologic disease, it doesn't start in the skin, and its damage may be more than skin deep.

At a basic level, psoriasis is a disorder of the immune system. White blood cells called T-helper lymphocytes become overactive, producing excess amounts of cytokines, such as tumor necrosis factor, interleukin-2, and interferon-gamma. In turn, these chemicals trigger inflammation in the skin and other organs. In the skin, the inflammation produces three characteristic findings: widened blood vessels, accumulation of white blood cells, and abnormally rapid multiplication of keratinocytes, the main cells in the outer layer of the skin. In healthy skin, keratinocytes take about a month to divide, mature, migrate to the skin surface, and slough off to make way for younger cells. But in psoriasis, the entire process is speeded up to as little as three to five days. The result is thickened, red skin that sheds silvery scales of keratinocytes that have matured before their time (see Figure 1).

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Link:
Psoriasis: More than skin deep - Harvard Health

A consensus was reach on 20 of the 21 proposals regarding dosing of methotrexate in patients with psoriasis, which investigators of the eDelphi study believed could be use to harmonize the treatment of the drug in affected patients.

As one of the 4 available systemic treatments, methotrexate has been prescribed for psoriasis for over 6 decades, and is also used prominently in the rheumatology field.

However, methotrexate was approved by the US Food and Drug Administration before the introduction of dose ranging studies. As such, a clear dosing regimen for the treatment is lacking.

As such, investigators led by Astrid van Huizen, MD, Department of Dermatology at the University of Amsterdam, conducted the eDelphi study to reach international consensus on the dosing of methotrexate for treating patients with psoriatic disease.

The study consisted of 3 sequential survey rounds that were conducted in September 2020, November 2020, and February 2021. An online consensus meeting occurred following the last survey round in June 2021.

A total of 4500 members of the Skin Inflammation and Psoriasis International Network (SPIN) were invited to participate. Additional emails were sent to 108 national representatives and 35 scientific committee members of the network.

From September 2020 to March 2021, a total of 180 participants worldwide- 30.6% of whom resided in non-Western countries- completed the 3 survey rounds.

Participants voted on 21 individuals proposals on a 9-point scale, 1-3 indicated disagree, 4-6 neither agree nor disagree, and 7-9 being agree.

A majority of participants worked at a university hospital (53.9%) and were experienced in treating patients with psoriasis with methotrexate (91.6%), with more than 10 years of experience.

Among the 251 participants included in the study, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting.

No consensus was achieved regarding increased dosage of folic acid when increasing the dosage of methotrexate, with members of the study citing a lack of conclusive evidence.

However, a consensus was met regarding children and methotrexate dosing, though most proposals were based on studies from rheumatology due to a lack of evidence in dermatology.

The most widely discussed proposals involved patients with frailty. Elderly individuals, individuals with kidney renal dysfunction, liver disorders (eg, nonalcoholic steatohepatitis), ulcerative colitis, history of hepatitis, lack of compliance, gastritis, diabetes, previous cancer, and congestive heart failure were included in the added definition of patients with frailty.

Furthermore, the term patients with frailty was replaced with vulnerable patient, which excluded elderly patients and patients with impaired kidney function.

While a consensus was achieved in the study, investigators believed that additional high-quality studies were needed to support the proposals offered by the group.

Other consensus projects can focus on the screening and monitoring of this drug, how often and which tests should be performed, and whether special precautions are needed in children, elderly individuals, and other subpopulations, the team wrote.

The statement, "International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis," was published online in JAMA Dermatology.

Continued here:
20 Proposals on Methotrexate Dosing in Patients with Psoriasis Discussed - MD Magazine

Who remembers the sweet 9-year-old girl, Yaelle from Dr Pimple Popper? Yaelle was featured on Season 5 during the episode entitled, Cyster Cyster and quickly captivated fans attention with her bubbly and charismatic personality. Unfortunately, she suffered from a serious case of psoriasis that covered her entire body and she went on the show in hope that Sandra Lee could help her.

The epic episode contained many bizarre situations including the twin sisters that both had cysts, however, Yaelle was the stand out star of the show and fans want to know what happened to her and if she managed to get her psoriasis sorted. Keep reading to find out!

BridTV

9139

Lucy and Desi | Official Trailer | Amazon Prime Video

https://i.ytimg.com/vi/Lw1h7olYRTY/hqdefault.jpg

978532

978532

center

22403

Yaelle is from a town called Hotchkiss in Colorado and at just nine years old she had suffered from extreme psoriasis all the way from her arms, neck, legs and head from a very young age and her condition was so bad that she said the skin often clogged up her ears.

The little girl had suffered from the condition since she was a baby, however, it started off only around her eyes and belly button but when she was nine it quickly flared up across her entire body.

Heartbreakingly, Yaelle opened up about how embarrassed she was by her condition and how she would style her hair specifically to try and cover it on her face. Her mom had tried to get her medications and steroids but none of them worked and only seemed to make it worse, so they finally decided to see Dr Lee in hopes of a miracle.

They drove all the way from Colorado to California to see the pimple popper and its safe to say it was worth the trip.

During the consultation, Lee described the many treatment options that were available for Yaelles condition but explained how most are too intense and dangerous.

However, we all know how amazing Dr Lee is and she obviously had a plan. The family had only been used to more old-fashioned treatment methods but Lee was here to introduce them to some new ones.

Dr Lee explained an amazing new medication that was only required to be taken once every three months by injection and said the results are usually spectacular. Yaelle was quick to jump at the opportunity and was very brave while receiving the injection.

At the end of the episode, we got to see Yaelle a few months later and fans were gobsmacked. The transformation was incredible and her psoriasis was almost cleared. Yaelle was over the moon and said she finally felt like me again.

During the episode we heard the pain Yaelles mother was going through from having to see her daughter suffer so much, she opened up about the familys Jewish religion and how they strive to live a self-sustaining, off-grid lifestyle.

The only issue with this was that the mom said it affected her daughter due to them being so far away from most towns it was hard for them to get doctors out and treat her psoriasis.

The family grow their own food and products and Yaelle was clear about how much she loves the outdoors so we are over the moon that she can finally enjoy it to its fullest!

WATCH DR PIMPLE POPPER ON TLC EVERY WEDNESDAY AT 9/8C

ANDGET FREAKY WITH US ONINSTAGRAMANDFACEBOOK

Niamh is a multi-faceted journalist with speciality interests in entertainment, lifestyle and culture. She recently graduated from the University of South Wales with a degree in Journalism and enjoys writing features, reviews and trending news stories.

See original here:
Dr Pimple Popper changed 9-year-old Yaelles life forever with genius treatment - Reality Titbit - Celebrity TV News

The new report by Expert Market Research titled, GlobalPsoriatic Arthritis Treatment MarketReport and Forecast 2021-2026, gives an in-depth analysis global psoriatic arthritis treatment market, assessing the market based on drug class, product type, route of administration, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/psoriatic-arthritis-treatment-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

In addition to the rise in biological and biosimilar therapies, there is an increase in the prevalence of psoriatic arthritis and an increase in R&D activities to develop novel drugs for the treatment of psoriatic arthritis. There is also an increase in demand for psoriatic arthritis treatment goods, along with an increase in the elderly population. High treatment costs and a lack of standardised diagnostic technologies, on the other hand, are projected to restrain market expansion.

Industry Definition and Major Segments

Psoriatic arthritis is a spondylarthritis-related inflammatory joint disease caused by psoriasis. Skin and musculoskeletal systems are both affected. Genetics and the environment both play a role in its development. Psoriatic arthritis symptoms include swollen toes, fingers, and joints, and pitted nails and discomfort.

Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/psoriatic-arthritis-treatment-market

On the basis of its drug class, the market can be widely categorised as:

Based on its product type, the market can be bifurcated as:

The different administration route available for psoriatic arthritis treatment are:

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Market Trends

More than half of the revenue share was captured by biologics in the Psoriatic Arthritis (PsA) Treatment market. The drug class is likely to increase at the fastest rate during the forecast period and maintain its dominance. The segments growth is expected to be bolstered by the good commercial performances of existing products and the upcoming releases of potential pipeline prospects.

North America and Europe accounted for over half of total revenue. North America led the regional markets, mostly due to product sales in the United States. There is also a substantial patient pool and significant manufacturers supporting the PsA treatment market expansion. Asia Pacific is predicted to be one of the fastest expanding areas. Biosimilars are a crucial growth driver in emerging economies including China, India, and South Korea. Regional expansion is also likely to be influenced by overall economic development, healthcare infrastructure improvements, rising disposable income, and consumer awareness.

Key Market Players

The major players in the market are AbbVie Inc., Amgen, Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc., UCB S.A, and AstraZeneca plc, among others. The report covers the market shares, capacities, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

Media Contact

Company Name: EMR Inc.Contact Person: Steven Luke, Corporate Sales Specialist U.S.A.Email:sales@expertmarketresearch.comToll Free Number: +1-415-325-5166 | +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USACity: SheridanState: WyomingCountry: United StatesWebsite:https://www.expertmarketresearch.com

Read More Reports:

Global Calcium Carbide Market:https://www.expertmarketresearch.com/reports/calcium-carbide-market

Global Wireline Services Market:https://www.expertmarketresearch.com/reports/wireline-services-market

Global Oilfield Services Market:https://www.expertmarketresearch.com/reports/oilfield-services-market

Global vegetable protein market:https://www.expertmarketresearch.com/reports/vegetable-protein-market

Global Reishi Mushroom Extract Market:https://www.expertmarketresearch.com/reports/reishi-mushroom-extract-market

Also, CheckProcurement Intelligencewhich provides you with Infallible research solutions.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Visit link:
Global Psoriatic Arthritis Treatment Market to be Driven by Rising Incidence of Psoriatic Arthritis and Extreme Symptoms in the Forecast Period of...

Upadacitinib has already been found to be safe and effective in the phase 3 SELECT-PsA 1 and 2 studies on patients with active psoriatic arthritis (PsA), as well as among patients with active ankylosing spondylitis (AS) in the phase 2/3 SELECT-ASXIS 1 study.

However, a new investigation compiled the data from all 3 randomized trials which brought more insight on upadacitinib's effect. Patients with active psoriatic arthritis or ankylosing spondylitis displayed rapid and sustained improvements in pain outcomes with upadacitinib for over a year.

The population included patients who have experienced either inadequate responses to non-biologic or biologic disease-modifying antirheumatic drugs (DMARDs), or were biologic-naive with inadequate response to non-steroidal anti-inflammatory drugs. Improvements were consistent and observed across several endpoints.

In all 3 studies, patients were randomized to receive either upadacitinib 15 mg once daily, or placebo. In SELECT-PsA 1, an additional group was administered adalimumab 40 mg every other week. Investigators, led by Iain B McInnes, MD, PhD, University of Glasgow, College of Medical, Veterinary and Life Sciences, evaluated pain outcomes based on increments.

In post hoc analyses, when compared with baseline, outcomes were measured by the proportion of patients who achieved 30%, 50% and 70% reduction using a patient global assessment of pain.

Also, changes from baseline were assessed at specific time points, as were particular questions from Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Additional end points that were unique to each study were looked at.

The research showed that a higher proportion of patients who received upadacitinib acheived 30%, 50% and 70% reduction in pain end points compared with placebo.

The improvements were observed as early as week 2 and were sustained or further increased through the first year (PsA 1/2 studies: 64%/48%, 58%/42% and 38%/22%, respectively; SELECT-AXIS 1 study: 76%, 72% and 54%). The data regarding adalimumab from the SELECT-PsA 1 study produced similar results (59%, 49% and 32%).

Patients who switched from placebo to upadacitinib 15 mg were able to improve to similar levels of the continuous upadacitinib group by the end of year 1 (PsA 1/2 studies: 46%60%, 35%49% and 15%34%; AS study: 83%, 72% and 46%).

Investigators pointed to the importance of pain management in these populations a key component to the treatment of psoriatic arthritis and ankylosing spondylitis. Pain has an incredible impact on an individual's quality of life, fatigue, and functional work impairment.

The study "Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials" was published in RMD Open Rheumatic & Musculoskeletal Diseases.

More here:
Upadacitinib Improves Pain Associated with Ankylosing Spondylitis, PsA - MD Magazine

Author: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, 1997. Revised August 2014. Skin of colour update: Dr Chelsea Jones, Resident Medical Officer, John Hunter Hospital, Newcastle, NSW, Australia; Dr Monisha Gupta, Dermatologist, University of NSW and Western Sydney University, Sydney, NSW, Australia. December 2020.

Psoriasis is a chronic inflammatory skin condition characterised by clearly defined, red and scaly plaques. It is classified into a number of types.

Psoriasis affects 24% of males and females. It can start at any age including childhood, with peaks of onset at 1525 years and 5060 years. It tends to persist lifelong, fluctuating in extent and severity. It is particularly common in Caucasians but may affect people of any race. About one-third of patients with psoriasis have family members with psoriasis.

Psoriasis is multifactorial. It is classified as an immune-mediated inflammatory disease (IMID).

Genetic factors are important. An individual's genetic profile influences their type of psoriasis and its response to treatment.

Genome-wide association studies report that the histocompatibility complex HLA-C*06:02 (previously known as HLA-Cw6) is associated with early-onset psoriasis and guttate psoriasis. This major histocompatibility complex is not associated with arthritis, nail dystrophy, or late-onset psoriasis.

Theories about the causes of hyperproliferation of the skin in psoriasis need to explain why the skin is red, inflamed, and thickened.

It is clear that immune factors and inflammatory cytokines (messenger proteins) such as IL1 and TNF are responsible for the clinical features of psoriasis. Current theories are exploring the TH17 pathway and release of the cytokine IL17A.

Psoriasis usually presents with symmetrically distributed, red, scaly plaques with well-defined edges. The scale is typically silvery white, except in skin folds where the plaques often appear shiny with a moist peeling surface. The most common sites are scalp, elbows, and knees, but any part of the skin can be involved. The plaques are usually very persistent without treatment.

Itch is mostly mild but may be severe in some patients, leading to scratching and lichenification characterised by thickened leathery skin and increased skin markings. Painful skin cracks or fissures may occur.

When psoriatic plaques clear up, they may leave brown or pale marks that can be expected to fade over several months.

Certain features of psoriasis can be categorised to help determine appropriate investigations and treatment pathways. Overlap may occur.

Post-streptococcal acute guttate psoriasis

Guttate psoriasis

Chronic plaque psoriasis

Flexural psoriasis

Scalp psoriasis

Sebopsoriasis

Palmoplantar psoriasis

Nail psoriasis

Erythrodermic psoriasis

Generalised pustulosis and localised palmoplantar pustulosis are no longer classified within the psoriasis spectrum.

Plaque psoriasis is the most common type of psoriasis in all racial groups. Non-Caucasians tend to have more extensive skin involvement than Caucasians. Asian populations are reported to have the highest percentage of body surface area involvement. In skin of colour the plaques are typically thicker with more pronounced silver scale and itch. The pinkness of early patches may be more difficult to appreciate resulting in a low PASI assessment. The thick plaques may appear violet or dark in colour. Plaque psoriasis commonly resolves to leave hyperpigmentation or hypopigmentation in skin of colour, which further impacts quality of life even after disease clearance.

Other types of psoriasis show variable rates in different skin types. Palmoplantar psoriasis is reported to be most common in the Indian population. Non-Caucasians are more likely to present with pustular and erythrodermic psoriasis than Caucasians, whereas flexural psoriasis is said to occur at a lower rate in skin of colour.

Plaque psoriasis in skin of colour

Patients with psoriasis are more likely than others to have associated health conditions such as are listed here.

Psoriasis is diagnosed by its clinical features. If necessary, diagnosis is supported by typical skin biopsy findings.

Medical assessment entails a careful history, examination, questioning about the effect of psoriasis on daily life, and evaluation of comorbid factors.

Validated tools used to evaluate psoriasis include:

The severity of psoriasis is classified as mild in 60% of patients, moderate in 30% and severe in 10%.

Evaluation of comorbidities may include:

Patients with psoriasis should ensure they are well informed about their skin condition and its treatment. There are benefits from not smoking, avoiding excessive alcohol, and maintaining optimal weight.

Mild psoriasis is generally treated with topical agents alone. Which treatment is selected may depend on body site, extent and severity of psoriasis.

Most psoriasis centres offer phototherapy(light therapy) with ultraviolet (UV) radiation, often in combination with topical or systemic agents.

Moderate to severe psoriasis warrants treatment with a systemic agent and/or phototherapy. The most common treatments are:

Other medicines occasionally used for psoriasis include:

Systemic corticosteroids are best avoided due to a risk of severe withdrawal flare of psoriasis and adverse effects.

Biologics or targeted therapies are reserved for severe psoriasis resistant to conventional treatment mainly because of expense, as side effects compare favourably with other systemic agents. They can also be used to treat concurrent psoriatic arthritis. These treatment include:

Many other monoclonal antibodies are under investigation in the treatment of psoriasis.

Oral agents working through the protein kinase pathways are also under investigation. Several JAK (Janus kinase) inhibitors are under investigation for psoriasis, including tofacitinib and the TYK2 (tyrosine kinase 2) inhibitorBMS-986165; both are in Phase III

Continue reading here:
Psoriasis: Symptoms, Treatment, Images and More - DermNet

People with psoriasis have an increased risk of developing psoriatic arthritis (PsA). New research shows that psoriasis severity and body surface area play a role in determining the extent of the risk.

Psoriasis is a chronic, autoimmune disease that affects the skin, causing dry, itchy patches with a covering of scales. In the United States, more than 7.5 million adults are living with this skin condition, which equates to about 3% of the adult population.

PsA is a chronic, inflammatory type of arthritis that leads to symptoms such as joint pain, stiffness, and swelling. Although it is possible to develop PsA without having psoriasis first, up to 34.7% of people living with psoriasis worldwide develop PsA.

The collective name for these two conditions is psoriatic disease. Researchers have looked into the link between these conditions and how they affect one another. Of particular interest are predictive symptoms that may indicate whether a person with psoriasis will also develop PsA.

More recently, researchers have looked at how the severity of psoriasis may affect the onset of PsA. A 2021 study showed a correlation between more severe cases of psoriasis and the development of PsA.

This article explores what experts know about the connections between psoriasis severity and PsA.

Over the years, researchers have studied the connection between psoriasis and PsA. Part of what they have looked for is trends in symptoms that may predict the likelihood that a person with psoriasis will develop PsA, as well.

As more than one-third of people living with psoriasis may also develop PsA, understanding what risk factors to look for may help doctors diagnose the joint condition sooner. The earlier diagnosis and treatment of PsA may lead to better outcomes and improved quality of life.

In a 2009 study, researchers found that the presence of certain psoriasis symptoms may increase a persons risk of developing PsA. The findings showed a link between the presence of the following psoriasis symptoms and an increased risk of PsA:

In another study from 2010, researchers shared similar results. They noted that the following psoriasis symptoms or factors were positively associated with an increased risk of developing PsA:

Research is beginning to show that the severity of a persons psoriasis may indicate that they have an increased risk of developing PsA.

In one older study from 2010, researchers acknowledged that severe cases of psoriasis increased a persons risk of developing PsA.

In a more recent 2021 study, researchers noted the same association. However, they cautioned that these findings might not be generalizable to the larger population.

In another 2021 study, researchers argued that the total body surface area that psoriasis covers may help predict the likelihood of developing PsA. The study authors also noted depression and obesity as additional risk factors.

The Global Healthy Living Foundation notes that although anyone living with psoriasis can develop PsA, psoriasis that covers a larger area of the body puts people at higher risk.

The organization also lists additional risk factors that could influence whether a person with psoriasis goes on to develop psoriatic arthritis. These factors include:

Growing evidence suggests that the severity of psoriasis symptoms, including the amount of the body that they affect, directly corresponds with the risk of developing psoriatic arthritis.

People who receive a diagnosis of psoriasis should talk with the doctor about their individual risk of developing PsA. They should also inform the doctor if they start to experience any joint symptoms that may indicate PsA.

More here:
Psoriasis severity, body surface area, and psoriatic arthritis - Medical News Today

John Tesser, MD: Lets talk about successful outcomes and maybe measures of successful outcomes. What are our goals in treating patients? Let me frame this in the context of how we view or have measured rheumatoid arthritis. That has been an ongoing battle and a challenge for rheumatologists for decades: measuring rheumatoid arthritis using either the Disease Activity Score, the Clinical Disease Activity Index, RAPID3 [Routine Assessment of Patient Index Data 3], some of those, all of those, none of those. We appreciate very much that the ACR20 [American College of Rheumatology 20% improvement], ACR50, and the ACR70 improvement criteriawhich are used in judging success in clinical trialsare not used at all in clinical practice. Its a composite measure of many things, but that measure in and of itself doesnt identify how much inflammatory disease a person has at any given point in time.

In psoriatic arthritis, interestingly enough, ACR20, ACR50, and ACR70 in clinical trials are utilized as the measure of success for FDA approval for psoriatic arthritis trials. Its not the only thing thats measured, but the ACR20 is used as the lowest bar for approval. The CDAI [Clinical Disease Activity Index] is beginning to be used by some people.

But theres another measurement thats analogous to the ACR composite criteria. Its called the minimal disease activity index. It comprises similar things to whats in the ACR criteria, like how many tender and swollen joints and whats the patients global and pain, functionality, and acute phase reactantthis kind of thing. Its all put together, and if you measure these things on your patient, then you assign certain points to these things. If the patients meet many points, theyre identified as having low disease activity; even more points, very low disease activity. That measure exists. It has begun to be used in clinical trials. Nehad, do you think this is going to have any utility in clinical practice? What do you do in your practice in terms of identifying outcome measures? When you think youve achieved success, how do you assess it?

Nehad Soloman, MD: For a long time, we grappled with this, or at least I grappled with this: what do I use as an outcome measure? Just like with the drugs, we borrowed things from the rheumatoid arthritis experience. When you mentioned the ACR levels, you also mentioned CDAI.The easiest thing to do was obviously the CDAI, which measures tender and swollen joints and assessment both by physician and patient in terms of global experience. But when you think about minimal disease activity index, it also measures tender joints, swollen joints. It looks at the skin, body surface area, and PASI [Psoriasis Area and Severity Index]. It looks at visual analog scales from a pain perspective as well as a global perspective. Then it also looks at the HAQ [Health Assessment Questionnaire] and it adds the other critical point, which we do clinically but we dont quantify it by looking at enthesitis or entheseal point tenderness.

Beyond that, as Ive learned to examine this a bit closer, its meeting 5 of 7 areas and having them at a level of 1 or less in some areas, 3 or less if youre talking about body surface area. But theres a target at each of these. The challenge, although we do a lot of this in clinical practice, just like the ACR scores, we just dont quantify it. We say, Theres an improvement in tender joints or swollen joints, or SED [erythrocyte sedimentation] rate and CRP [C-reactive protein] have improved or have normalized. Thats the quick and dirty way of saying theyre getting better.

As payers demand and as patients demand a number or a target, we may find ourselves using this. To employ this so that we can inform treatment decisions, the world of IT [information technology] is going to meet medicine once more and find a way to make itself into our EHR [electronic health record] in a manner thats simple. If just like in our EHR, we can quickly insert these, whether part of it is imported from the patient questionnaire or part of it is actively recorded as were seeing the patient, then it may very well become more mainstream. But it will be years down the line when we can get this to be streamlined in the EHR.

John Tesser, MD: Those are very good points. I find it very interesting that this particular composite measure, as opposed to the ACR, does identify a certain amount of disease. But psoriatic disease is difficult because there are many domains. Its not so easy to incorporate all these things into 1 overall grouping. Its a fairly reasonable attempt, and perhaps over time well use it more and more.

This transcript has been edited for clarity.

Read the rest here:
Measuring Outcomes for the Treatment of Psoriatic Arthritis - MD Magazine

Phase 2b clinical trial of PN-235, an oral IL-23 receptor antagonist, has launched with a target enrollment of 240 patients

NEWARK, Calif., March 16, 2022 /PRNewswire/ --Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today earning a $25 million milestone payment from its collaboration with Janssen Biotech Inc., (Janssen), following dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113).

"The start of this Phase 2b study in moderate-to-severe plaque psoriasis marks an exciting moment along the development pathway for this promising drug candidate, discovered through Protagonist's proprietary technology platform," said Dinesh V. Patel, Ph.D., President and CEO of Protagonist. "Advancing PN-235 aligns with our shared goal with Janssen to develop new therapies with transformational potential for patients in need."

FRONTIER 1 is a Phase 2b multicenter, randomized, placebo controlled, dose-ranging study to evaluate the safety and efficacy of PN-235 for the treatment of moderate-to-severe plaque psoriasis. This study commenced on February 3, 2022 and is expected to enroll 240 participants. More information on FRONTIER 1 can be found at clinicaltrials.gov.

Protagonist has granted Janssen an exclusive worldwide license to research, develop and commercialize oral IL-23 receptor antagonists based on the Company's intellectual property. Current development efforts are centered on PN-235, discovered by Protagonist and further developed in collaboration with Janssen.

Protagonist is eligible for up to approximately $850 million in development-related milestone payments, in addition to $112.5M in milestones already earned. Under terms of the collaboration, Janssen will conduct all future clinical studies, inclusive of Phase 2 and 3 studies. Janssen will be financially responsible for such studies.

About Protagonist

Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based new chemical entities in different stages of clinical development, all derived from the Company's proprietary technology platform.

Protagonist's pipeline includes rusfertide, an investigational, injectable hepcidin mimetic currently in the REVIVE Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), the PACIFIC Phase 2 study in PV subjects with high hematocrit levels, and a recently completed Phase 2a study for hereditary hemochromatosis. The Company is actively initiating VERIFY, a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.

The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943), currently in the IDEAL Phase 2 study in adults with moderate to severe active ulcerative colitis. The Company is targeting ulcerative colitis as the initial indication.

Protagonist has granted Janssen an exclusive worldwide license to research, develop and commercialize oral IL-23 receptor antagonists based on the Company's intellectual property. Current development efforts are centered on PN-235, discovered by Protagonist and further developed in collaboration with Janssen.

Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, future PN-235 clinical studies and the potential for drug candidates developed in our Janssen collaboration. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements, the impact of the current COVID-19 pandemic on our discovery and development efforts, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-earns-25-million-milestone-payment-from-janssen-biotech-for-dosing-of-third-patient-in-phase-2b-clinical-trial-of-pn-235-in-moderate-to-severe-plaque-psoriasis-301503561.html

SOURCE Protagonist Therapeutics Inc.

View original post here:
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in...